Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose reduction of lubiprostone after nausea/vomiting in chronic constipation
jRCTs031180069Completed
- Sponsor
- Mylan
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cobiprostone in chronic constipation, sponsored by Mylan. Primary endpoint: Lubiprostone treatment continuation rate after onset of nausea or vomiting. Started Jan 2019; status: completed.
02
Drugs
cobiprostone
03
Conditions
chronic constipation
Beyond the preview
Go deeper on jRCTs031180069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180069.